Similarly, in this BC population, modifiable CV risk factors were not associated with LVD occurrence and its risk was mostly driven by the inherent toxicity of anticancer treatments, such as combined anti-HER2 therapy. This evidence concerns the gene ERBB2 and breast cancer.